Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

Company Overview

Eloxx Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions.

Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations. Eloxx evaluated ELX-02 primarily for cystinosis, a rare inherited disorder caused by mutations in the CTNS gene, and also explored potential applications in other genetic conditions, including cystic fibrosis.

The company was formerly known as Zikani Therapeutics and conducted research and development activities in the United States and Israel, including work through its Israeli operations. Eloxx was a development-stage company and did not have an established portfolio of marketed products. Public information about its later operations and leadership is limited, and the company’s status changed substantially after its development programs were advanced.

Key Stats

• Today's Range: $15.60 to $16.71
• 50-Day Range: $11.65 to $20.98
• 52-Week Range: $8.20 to $23.40
• Volume: 28,902 shs
• Average Volume: 30,860 shs
• Market Capitalization: $64.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.33
• Consensus Rating: Buy

Eloxx Pharmaceuticals Stock Analysis - MarketRank™

Eloxx Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 536th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Eloxx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Eloxx Pharmaceuticals has a consensus price target of $38.33, representing about 139.6% upside from its current price of $16.00.

Amount of Analyst Coverage

Eloxx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Eloxx Pharmaceuticals is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eloxx Pharmaceuticals is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.53% of the float of Eloxx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eloxx Pharmaceuticals has a short interest ratio ("days to cover") of 1.38, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eloxx Pharmaceuticals has recently increased by 58.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eloxx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eloxx Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 6 news articles for Eloxx Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for ELOX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.90% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ELOX
• CIK: 1035354
• Web: www.eloxxpharma.com
• Phone: 781-577-5300
• Fax: 908-864-4440
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eloxx Pharmaceuticals: $38.33
• High Price Target: $43.00
• Low Price Target: $32.00
• Potential Upside/Downside: +139.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.74
• Quick Ratio: 3.74

Sales & Book Value

• Annual Sales: $6.36 million
• Price / Sales: 10.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($85.17) per share
• Price / Book: -0.19

Miscellaneous

• Outstanding Shares: 4,040,000
• Free Float: 2,991,000
• Market Cap: $64.64 million
• Optionable: N/A
• Beta: -1,862.26